Home / Intelligence / Case Studies / Improving Targeting Precision and Field Force Direction through AIML-based Patient Finding
Background
- A global rare disease company was looking to improve targeting precision and support field team effectiveness
- Traditional targeting was non-viable due to the small size of the patient populations, complex disease recognition and diagnosis, and restrictive therapy eligibility criteria
- Attempts by a prior analytics partner to use rule-based alerts failed, and even after two years, no new patients had been identified
- Given the small number of patients in each indication, every new start is high value, both for the lives of patients in need and for the commercial success of the therapies
Trinity’s Solution
- Create an AIML model that identifies clinically on-label patients—rather than simply patients with the disease
- ‘Learn’ from on-therapy patients to identify how patients present prior to therapy initiation and execute AIML models to flag patients based on the probability that they are candidates for treatment
- Deploy bifurcated notifications to both inside and field-based reps through ‘push’ alerts within the client’s CRM and enable ‘pull’ solutions to support call planning
- Success drivers include:
- Data acumen to evaluate and select source data
- Therapeutic area expertise
- Deep collaboration with Medical to refine and calibrate models
- AIML experience to optimize feature selection and approach
Project Outcomes
![](https://trinitylifesciences.com/wp-content/uploads/2023/03/AIML-Case-Study1.png)
Designed and deployed AIML models for three indications in 8 weeks
![](https://trinitylifesciences.com/wp-content/uploads/2023/03/AIML-Case-Study2.png)
Narrowed field team focus from >25,000 HCPs to ~1,000 highest priority HCPs
![](https://trinitylifesciences.com/wp-content/uploads/2023/03/AIML-Case-Study3.png)
Identified 100 high probability targets within first 2 months of launch
![Patients confirmed through Machine learning.](https://trinitylifesciences.com/wp-content/uploads/2023/03/AIML-Case-Study4.png)
At least 5 patients confirmed to be clinically on-label for therapy within first 2 months
![Generative AI](https://trinitylifesciences.com/wp-content/uploads/2023/03/AIML-Case-Study5-1.png)
First new patient enrolled within 5 weeks of initiating alerts
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.
Related Intelligence
Blog
The Next Wave of Global AI Medical Devices: Innovation in Action
A recent bipartisan initiative by Senators Martin Heinrich, Mike Rounds, Marsha Blackburn and Todd Young urged the Centers for Medicare & Medicaid Services (CMS) to establish a formal payment pathway for algorithm-based health care services (ABHS). This move addresses the need for stable Medicare reimbursement for FDA-cleared AI and machine learning (ML) medical devices, which […]
Read More
Webinars
Human Centered Design Approach to GenAI for Life Sciences
Available On Demand
We need to think through not just whether GenAI works, but how we make it usable for people and impactful for our business… The next webinar in our “Making AI Real” webinar series will focus on people, process and technology—three interconnected components that are key to successful GenAI implementation. Join Trinity Life Sciences’ GenAI experts […]
Watch Now
Case Studies
HCP-level Site Alert Predictions
Trinity was able to develop an advanced machine learning algorithm to predict potential site alerts for HCPs in the target universe
Read More